` SLDB (Solid Biosciences Inc) vs S&P 500 Comparison - Alpha Spread

SLDB
vs
S&P 500

Over the past 12 months, SLDB has underperformed S&P 500, delivering a return of -28% compared to the S&P 500's 9% growth.

Stocks Performance
SLDB vs S&P 500

Loading
SLDB
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
SLDB vs S&P 500

Loading
SLDB
S&P 500
Difference
www.alphaspread.com

Performance By Year
SLDB vs S&P 500

Loading
SLDB
S&P 500
Add Stock

Competitors Performance
Solid Biosciences Inc vs Peers

S&P 500
SLDB
ABBV
AMGN
GILD
VRTX
Add Stock

Solid Biosciences Inc
Glance View

Market Cap
360.3m USD
Industry
Biotechnology

Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy (DMD). The company is headquartered in Cambridge, Massachusetts and currently employs 104 full-time employees. The company went IPO on 2018-01-26. Duchenne is a genetic muscle-wasting disease predominantly affecting boys. SGT-001 and SGT-003 are its gene transfer candidates. SGT-001 and SGT-003 are designed to address the underlying genetic cause of Duchenne by delivering a synthetic transgene that produces dystrophin-like protein that is only expressed in muscles of the body, including cardiac and respiratory muscles. SGT-001 is its lead gene transfer candidate and utilizes an adeno-associated virus (AAV)9 vector. In addition to its gene transfer candidates, it has development programs focusing on platform technologies, including dual gene expression, a technology that allows it to package multiple transgenes into one vector, as well as capsids. The company is developing SGT-001 for the treatment of Duchenne through a single intravenous administration.

SLDB Intrinsic Value
Not Available
Back to Top